Frankfurt CRISPR/Cas Screening Center (FCSC)

 

General

The recently introduced CRISPR/Cas technology has induced an unprecedented biological revolution. As such, there is an increasing demand on gene editing technologies, including single to multiple gene knockouts, transcriptional activation/repression, targeted single nucleotide modification or the precise replacement of genetic loci for the purpose of tagging or modification.
To meet the increasing demand within the Institute and the local community, the IBC2 has built up the Frankfurt CRISPR/Cas Screening Center (FCSC), led by Ivan Dikic and Manuel Kaulich. On the basis of collaboration, the platform supports both internal and external researchers with expertise, reagents and strategic advice on gene editing. The FCSC guides researches along their individual needs, ranging from single to multiple gene editing events, specific gene replacements, to the generation of custom made gRNA libraries.
A recent example has been published by Kaulich and Dikic in collaboration with the groups of Simone Fulda and Mike Heilemann (van Wijk et al., Nature Microbiology, 2017). They discovered that the linear ubiquitin coat surrounding intracellular Salmonella serves as a signaling hub to locally activate NF-κB and thereby restrict bacterial proliferation. Within the project, the deubiquitinating enzyme OTULIN was identified as central regulator of M1-linked ubiquitin chains on bacterial coats. The FCSC generated OTULIN KO cells for the functional validation of this finding. This prominent example underlines the importance of employing cutting-edge technologies on leading scientific questions and highlights the collaborative nature pursued with the FCSC at the IBC2.

Any requests for collaborations can be addressed to Manuel Kaulich (Email; 069/6301-5450) or Ivan Dikic ( (Email; 069/6301-5964).